Avanos Medical (AVNS)
(Delayed Data from NYSE)
$10.98 USD
-0.19 (-1.70%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $10.99 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, AVANOS MEDICAL, INC. has a PEG ratio of 1.29 compared to the Medical - Instruments industry's PEG ratio of 2.28.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVNS 10.98 -0.19(-1.70%)
Will AVNS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVNS
New Strong Sell Stocks for July 15th
Avanos Medical (AVNS) International Revenue in Focus: Trends and Expectations
AVNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for May 9th
AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
Other News for AVNS
Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical | AVNS ...
Avanos announces divestiture of Hyaluronic Acid product line to Channel-Markers Medical
Avanos divests Hyaluronic Acid product line to Channel-Markers Medical
Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2025 Financial ...
Avanos (AVNS) Welcomes New Chief Human Resources Officer | AVNS Stock News